Related Experiment Video

Updated: Aug 21, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Platelet activation in heart failure

Andreas Schäfer1, Martin Eigenthaler, Johann Bauersachs

  • 1Medizinische Klinik der Julius-Maximilians-Universität Würzburg, Germany. a.schaefer@medizin.uni-wuerzburg.de

Clinical Laboratory
|October 16, 2004
PubMed

Insights

Heart failure increases stroke risk due to abnormal platelet activation. This review explores heart failure

Area of Science:

  • Cardiology
  • Hematology
  • Vascular Biology

Background:

  • Heart failure is prevalent in aging populations, increasing stroke risk.
  • Both atrial fibrillation and hypercoagulable states contribute to thromboembolic events in heart failure.
  • Recent findings indicate enhanced platelet activation even in heart failure patients with sinus rhythm.

Purpose of the Study:

  • To review historical knowledge on abnormal platelet function in heart failure.
  • To focus on pathophysiological changes influencing platelet activation in heart failure.
  • To discuss therapeutic strategies targeting platelet activation in heart failure.

Main Methods:

  • Literature review of studies on heart failure and platelet function.
  • Analysis of pathophysiological mechanisms linking heart failure to platelet activation.
  • Examination of clinical trials investigating anti-platelet drug regimens.

Main Results:

  • Heart failure is associated with enhanced platelet activation, partly due to vascular endothelial dysfunction and reduced nitric oxide.
  • Mechanisms include endothelial dysfunction and impaired nitric oxide bioavailability.
  • Various drug regimens are being investigated for their anti-platelet effects.

Conclusions:

  • Abnormal platelet function is a significant contributor to cardiovascular events in heart failure.
  • Targeting platelet activation presents a potential therapeutic avenue.
  • Further research is needed to optimize drug regimens for reducing platelet activation in heart failure.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...